📰 Access Pathway News
Page 12 - Access Pathway News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Access Pathway. Real-time updates on events, politics, business and more.
April 15, 2023
U.K. regulators have granted an innovation passport to ADvantage's AD04 to help speed the therapy's development for early Alzheimer's.
April 12, 2023
Dr Christoph Zehendner, Medical Director of Boehringer Ingelheim UK and Ireland discusses the company’s ILAP designation for oncology.
April 10, 2023
LONDON, April 10, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to...
April 3, 2023
A rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, cell and... | April 3, 2023
April 3, 2023
-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- ... | April 3, 2023
March 28, 2023
IOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces that the innovative medicine designation, the Innovation Passport, has been awarded for roginolisib, for the...
March 2, 2023
/PRNewswire/ -- DelveInsights Asthma Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed, and pipeline asthma...
March 2, 2023
Asthma is a chronic disease that affects a substantial number of patients worldwide, including children, a number of pharmaceutical companies are involved in developing drugs for asthma. This
February 28, 2023
28.02.2023 - Highlights: Phase 3 pivotal program underway - important updates announcedPhase 3 long term follow up definedCash position at 31 December 2022 of $143.2 millionConference call today at 8:00am ET (1:00pm UK) LONDON, Feb. 28, 2023 (GLOBE NEWSWIRE) ...
February 28, 2023
Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in... | February 28, 2023